Paclitaxel-induced peripheral neuropathy (PIPN) is one of the most dose-limiting side effects; it causes patients discomfort and pain and sometimes causes the termination of the chemotherapy cycles, leading to treatment failure. A lot of interventions have been tried to prevent PIPN, ensure complete administration of the chemotherapy cycles, and increase the survival rate. One of the promising interventions in the prevention of PIPN is Losartan. Losartan is an angiotensin receptor blocker (ARBs) and is used to treat hypertensive patients. There is strong evidence from different preclinical studies and retrospective cohort studies that Losartan has a neuroprotective effect. The purpose of our study is to investigate the efficacy of Losartan in the prevention of peripheral neuropathy associated with Paclitaxel treatment in Breast Cancer patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Enrollment
84
Using losartan to prevent paclitaxel-induced peripheral neuropathy
Breast Cancer Comprehensive Center of the National Cancer Institute, Cairo University
Cairo, Egypt
Development of paclitaxel-induced peripheral neuropathy
Incidence and grading of paclitaxel-induced peripheral neuropathy (PIPN)
Time frame: 12 weeks
Patient QOL
Patient quality of life will be assessed by Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-NTX)
Time frame: 12 weeks
Pain Severity
Pain intensity will be assessed through Visaul Analogue Scale Scale 0-10
Time frame: 12 Weeks
Serum biomarker
Level of Nerve growth factor (NGF) in Serum
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.